Monitor Patent issues
Corporate Tax Reform
Excise Tax Issues
Health Care Extenders
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Obamacare Repeal
Health Care reform
Chip Reauthorization
Duration: November 1, 2007
to
December 31, 2018
General Issues: Copyright/Patent/Trademark , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Medicare/Medicaid , Health Issues , Budget/Appropriations , Advertising , Agriculture , Food Industry (Safety, Labeling, etc.) , Law Enforcement/Crime/Criminal Justice , Pharmacy
Spending: about $937,500 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, Administration for Children & Families (ACF), U.S. Trade Representative (USTR), U.S. Senate,, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
Policy Advocates terminated an engagement in which they represented GlaxoSmithKline on Feb. 4, 2019.
Original Filing: 301019729.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Excise Tax Issues
Health Care Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
3rd Quarter, 2018
In Q3, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Oct. 29, 2018.
Original Filing: 300999577.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Excise Tax Issues
Health Care Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
2nd Quarter, 2018
In Q2, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Aug. 31, 2018.
Original Filing: 300981399.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Excise Tax Issues
Health Care Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
1st Quarter, 2018
In Q1, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on April 27, 2018.
Original Filing: 300959346.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Excise Tax Issues
Health Care Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
4th Quarter, 2017
In Q4, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Jan. 15, 2018.
Original Filing: 300923815.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Alternative minimum Tax reform
Excise Tax Issues
Health Care Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
3rd Quarter, 2017
In Q3, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Dec. 9, 2017.
Original Filing: 300920119.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Alternative minimum Tax reform
Excise Tax Issues
Health Care Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
2nd Quarter, 2017
In Q2, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on July 20, 2017.
Original Filing: 300894110.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Alternative minimum Tax reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
USTR appointments
Patent Protection
NAFTA repeal and Renegotiation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation HR1628
Access to Affordable Prescription Drugs
Medicare Prescription Drug Price Negotiation Act HR 242
Protecting Medicare from executive Action S 251
Medicare Prescription Drug Price Negotiation Act S 41
Race for Children Act HR 1231
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
1st Quarter, 2017
In Q1, Policy Advocates lobbied for GlaxoSmithKline , earning $20,000. The report was filed on May 15, 2017.
Original Filing: 300880266.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Corporate Tax Reform
Alternative minimum Tax reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Health Care Reform Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Obamacare Repeal
Health Care reform
Chip Reauthorization
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
4th Quarter, 2016
In Q4, Cabralgroup lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Feb. 15, 2017.
Original Filing: 300860435.xml
Lobbying Issues
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045,TROL Act;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S 1946 Tax Relief Extension Act of 2015
HR 2029 Consolidated Appropriations Act, 2016.
H.R. 45 (113th): To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor 21st Century Cures Legislation, HR 6.
Consolidated and Further Continuing Appropriations Act, 2015 HR 83
S. 1878, The Advancing Hope Act of 2015
S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015
S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act
S. 2055, The Medical Countermeasures Innovation Act of 2015
S. 1767, The Combination Products Innovation Act of 2015
S. 1597, Patient Focused Impact Assessment Act of 2015
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
3rd Quarter, 2016
In Q3, Policy Advocates, LLC (Formerly Walker, Martin & Hatch, LLC) lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Oct. 19, 2016.
Original Filing: 300833917.xml
Lobbying Issues
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045,TROL Act;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S 1946 Tax Relief Extension Act of 2015
HR 2029 Consolidated Appropriations Act, 2016.
H.R. 45 (113th): To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor 21st Century Cures Legislation, HR 6.
Consolidated and Further Continuing Appropriations Act, 2015 HR 83
S. 1878, The Advancing Hope Act of 2015
S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015
S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act
S. 2055, The Medical Countermeasures Innovation Act of 2015
S. 1767, The Combination Products Innovation Act of 2015
S. 1597, Patient Focused Impact Assessment Act of 2015
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
2nd Quarter, 2016
In Q2, Policy Advocates, LLC (Formerly Walker, Martin & Hatch, LLC) lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Aug. 10, 2016.
Original Filing: 300823514.xml
Lobbying Issues
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045,TROL Act;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S 1946 Tax Relief Extension Act of 2015
HR 2029 Consolidated Appropriations Act, 2016.
H.R. 45 (113th): To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor 21st Century Cures Legislation, HR 6.
Consolidated and Further Continuing Appropriations Act, 2015 HR 83
S. 1878, The Advancing Hope Act of 2015
S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015
S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act
S. 2055, The Medical Countermeasures Innovation Act of 2015
S. 1767, The Combination Products Innovation Act of 2015
S. 1597, Patient Focused Impact Assessment Act of 2015
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
1st Quarter, 2016
In Q1, Policy Advocates, LLC (Formerly Walker, Martin & Hatch, LLC) lobbied for GlaxoSmithKline , earning $20,000. The report was filed on May 14, 2016.
Original Filing: 300805276.xml
Lobbying Issues
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045,TROL Act;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S 1946 Tax Relief Extension Act of 2015
HR 2029 Consolidated Appropriations Act, 2016.
H.R. 45 (113th): To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor 21st Century Cures Legislation, HR 6.
Consolidated and Further Continuing Appropriations Act, 2015 HR 83
S. 1878, The Advancing Hope Act of 2015
S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015
S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act
S. 2055, The Medical Countermeasures Innovation Act of 2015
S. 1767, The Combination Products Innovation Act of 2015
S. 1597, Patient Focused Impact Assessment Act of 2015
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
4th Quarter, 2015
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776691.xml
Lobbying Issues
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045,TROL Act;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S 1946 Tax Relief Extension Act of 2015
HR 2029 Consolidated Appropriations Act, 2016.
H.R. 45 (113th): To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor 21st Century Cures Legislation, HR 6.
Consolidated and Further Continuing Appropriations Act, 2015 HR 83
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
3rd Quarter, 2015
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Nov. 4, 2015.
Original Filing: 300767253.xml
Lobbying Issues
Monitor and shape:
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045, TROL Act H.R.;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor Tax Reform efforts
Monitor R & D tax extenders package
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Continue to educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor 21st Century Cures Legislation, HR 6.
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
2nd Quarter, 2015
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on July 15, 2015.
Original Filing: 300735497.xml
Lobbying Issues
Monitor and shape:
S. 1137, The Protecting American Talent and Entrepreneurship Act (PATENT Act);
H.R. 9, Innovation Act;
S. 632, STRONG Act;
H.R. 2045, TROL Act H.R.;
H.R. 3349,Innovation Protection Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor Tax Reform efforts
Monitor R & D tax extenders package
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor Trade Promotion Authority legislation, Trade Preferences Extension Act, Trade Adjustment Assistance, bills monitored and supported provisions related to Patent life.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Continue to educate Congress on value and success of Medicare Part D program and oppose efforts to undermine the program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 1470, SGR Repeal and Medicare Provider Payment Modernization Act, H R 2, Medicare Access and CHIP reauthorization, support the SGR Fix, Monitor 21st Century Cures Legislation, HR 6.
Agencies Lobbied
U.S. Senate Administration for Children & Families (ACF)
1st Quarter, 2015
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on June 15, 2015.
Original Filing: 300730628.xml
Lobbying Issues
PATENT Act (S. 1137)The Protecting American Talent and Entrepreneurship Act (PATENT Act)- Supporting and improving legislation to reflect Pharmaceutical and consumer interest.
S. 632, the STRONG Patents Act of 2015 monitor and review.
H.R. 9,the Innovation Act monitor and review legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
monitor progress on the House 21st Century Cures legislation and it's impact.
HR 1470 ,SGR Repeal and Medicare Provider Payment Modernization Act of 2015- support solution for issue.
H.R. 2, the Medicare Access and CHIP Reauthorization Act, support the SGR fix.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Educate Congress on Patient opposition to drug rebates in Medicare Part D. Proposed changes would undermine patient access to medicines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor Tax Reform preparation in the Senate and Hill as the Congress Tackles corporate and personal tax reform issues.
Monitor progress of Tax Extenders legislation in development.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Jan. 20, 2015.
Original Filing: 300705864.xml
Lobbying Issues
Patent Reform Legislation
Patent Litigation Integrity Act
Patent Transparence and Improvement Act
Patent Abuse Reduction Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Family Health Care Flexibility Act
Newborn Screening Saves Lives Reauthorization Act
Ryan White Patent Equity and Choice Act
Family Health Care Flexibility Act
Access to Appropriate Immunizations for Veterans Act
21st Century Cures
Limited Population Antibacterial Drug Act
Specialty Drug protection
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Prescription Drug Savings and Choice Act (Part D)
Medicare Drug Savings Act
Medicare Therapy Empowerment Act
Medicare Prescription Drug Price negotiation Act
Protecting Access to Medicare Act
SGR Repeal and Medicare Beneficiary Access Act
Issues related to medicare Part D
Issues related to SGR Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Nov. 10, 2014.
Original Filing: 300691043.xml
Lobbying Issues
Patent LegislationS. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements
S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements
S. 866 - Patent Quality Improvement Act of 2013; Business methods patents provisions
S. 1013 - Patent Abuse Reduction Act of 2013; provisions related to patent litigation reform
S. 1612 - Patent Litigation Integrity Act; Patent litigation provisions including bonding
S. 1720 - Patent Transparency and Improvements Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Health LegislationH.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
H.R. 1281 - Newborn Screening Saves Lives Reauthorization Act
H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval
H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP
H.R. 4847 - End Neglected Tropical Diseases Act
S. 539 - National Diabetes Clinical Care Commission Act
S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine
S. 1417 - Newborn Screening Saves Lives Reauthorization Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare medicaid legislationH.R. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board
H.R. 928 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D
H.R. 1024 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues
H.R. 1102 - Medicare Prescription Drug Price Negotiation Act of 2013; Provisions related to Part D issues and non-interference
H.R. 1588 - Medicare Drug Savings Act of 2013; provisions related to Part D issues
H.R. 2810 - Medicare Patient Access and Quality Improvement Act of 2013; Provisions related to SGR reform
H.R. 2827 - To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D; provisions related to Medicare Part D Drug Tier Formularies
H.R. 3890 - Better Care, Lower Cost Act; Provisions related to Part D, value-based insurance design, and chronic disease
H.R 4160 - Keep the Promise to Seniors Act of 2014; provisions related to Part D
H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act
H.R. 4302 - Protecting Access to Medicare Act of 2014 - provisions related to the biopharmaceutical industry
S. 117 - Medicare Prescription Drug Price Negotiation Act of 2013; provisions related to Part D issues
S. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board
S. 408 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D
S. 557 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues
S. 740 - Medicare Drug Savings Act of 2013; provisions related to Part D issues
S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; Provisions related to reforming Medicare physician payments
S. 1932 - Better Care, Lower Cost Act; Provisions related to Part D, value-based insurance design, and chronic disease
S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; Provisions related to SGR reform
S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; Provisions related to SGR reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Aug. 20, 2014.
Original Filing: 300672204.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2014
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on April 21, 2014.
Original Filing: 300647448.xml
Lobbying Issues
Freedom of Health Speech Act, Dietary supplement issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Public Law 113-79, Agricultural Act of 2014, Dietary supplement issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2015, provisions relating to dietary supplements
Department of Defense Appropriations Act, FY2015, track provisions relating to dietary supplements
Public Law 113-46, Continuing Appropriations Act, FY2014, generally
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Public Law 111-353, FDA Food Safety Modernization Act, Implementation issues regarding dietary supplement issues
Food Safety Accountability Act of 2011, entire bill as it relates to dietary supplements
S.1425, Dietary Supplement Labeling Act, entire bill as it relates to dietary supplements
Safe Cosmetics Act, entire bill as it relates to dietary supplementsSafe Cosmetics Act, entire bill as it relates to dietary supplements
Dietary Supplement Protection Act, entire bill as it relates to dietary supplements
Issues related to New Dietary Ingredients
H.R.1699/S.809, Genetically Engineered Food Right-to-Know Act, Dietary supplement issues
H.R.3147, Food Labeling Modernization Act of 2013, entire bill
Issues relating to energy drinks and caffeine
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Food Industry (Safety, Labeling, etc.)
Lobbying Issues
Issues regarding dietary supplements:
Dehydroepiandrosterone Abuse Reduction Act
Health Freedom Act
Public Law 113-54, Drug Quality and Security Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding dietary supplements:
Designer Anabolic Steroid Control Act
Dehydroepiandrosterone Abuse Reduction Act
Dimethylamylamine (DMAA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R.2194/S.1031, Family and Retirement Health Investment Act of 2013, Dietary supplement issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $20,000. The report was filed on Jan. 24, 2014.
Original Filing: 300629037.xml
Lobbying Issues
Agriculture Approps
FDA Funding
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1720 Patent Transparency and Improvemnets Act
S. 1612 Patent Litigation Integrity Act
S. 1013 Patent Abuse Reduction Act
S 866 Patent Quality Improvement ActHR 3309 Patent Inovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
HR 3204-Drug Quality and Security Act
HR 3742-Antibiotic Development Patient Treamnet Act
HR 1248-Family Health Care Flexibility Act
HR 2725-FDA Safety ovr Sequestration Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
TPA, TPP, TTIP trade issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2013
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Nov. 21, 2013.
Original Filing: 300610034.xml
Lobbying Issues
S. 959 Pharmaceuitical Compounding Quality and Accounting Act.
S. 957 Drug Supply Chain Security Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor TPP and TTIP trade issues
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Corporate Tax reform Legislation
Tax Reform Issues
Deficit reduction policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Aug. 1, 2013.
Original Filing: 300588250.xml
Lobbying Issues
Corporate Tax Reform Legislation
Deficit reduction policy issues
Tax Policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Trans-Pacific Strategic Economic Partnership Agreement (TPP)
Transatlantic Trade and Investment Partnership (TTIP)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
S. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements
S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2013
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on April 22, 2013.
Original Filing: 300564076.xml
Lobbying Issues
H.Con.Res. 25 - Fiscal 2014 House Budget Resolution - Provisions relating to Part D.
H.J.Res. 117 - FY 13 Continuing Appropriations Act - Provisions related to sequester implementation, FDA funding, oversight, trade, prescription drug abuse, comparative effectiveness research, NIH funding.
H.R. 933 - FY 13 Consolidated and Further Continuing Appropriations Act - Provisions related to sequester implementation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 8 - American Taxpayer Relief Act of 2012 (112th Congress) - provisions related to Medicare and Tax.
Tax Extenders
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Jan. 22, 2013.
Original Filing: 300542420.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient
Protection and Affordable Care Act; legislative issues related to pandemic influenza vaccine
development; and the Food and Drugs Administration legislative issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 8, American Taxpayer Relief Act of 2012
Family and Business Tax Cut Certainty Act of 2012, Tax Extenders related to R & D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2012
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Oct. 17, 2012.
Original Filing: 300509780.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Permanent Normal Trade Relations
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Sequestration and Tax Extenders
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2012
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on July 20, 2012.
Original Filing: 300498874.xml
Lobbying Issues
Prescription Drug User Fee Act
Medicare Part D
Drug Importation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trans-Pacific Partnership
Agencies Lobbied
U.S. Senate U.S. House of Representatives U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on April 20, 2012.
Original Filing: 300470536.xml
Lobbying Issues
PDUFA
Drug Importation Issues
2012 Budget
IPAB
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Jan. 18, 2012.
Original Filing: 300439970.xml
Lobbying Issues
Patent Reform, Budget, Taxes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Oct. 5, 2011.
Original Filing: 300410974.xml
Lobbying Issues
US Senate, US House of Reps.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on July 19, 2011.
Original Filing: 300398689.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 - Track and monitor.
H.R. 5: Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2011
WALKER, MARTIN & HATCH, LLC amended a lobbying report for representation of GlaxoSmithKline in Q12011 on Dec. 28, 2011.
Original Filing: 300433855.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 - Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2011
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on April 18, 2011.
Original Filing: 300368710.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 - Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2010
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Jan. 18, 2011.
Original Filing: 300342078.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011 - Track and monitor.
Track and monitor industry issues.
3rd Quarter, 2010
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Oct. 20, 2010.
Original Filing: 300322200.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011 - Track and monitor.
Track and monitor industry issues.
2nd Quarter, 2010
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on July 19, 2010.
Original Filing: 300294907.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011 - Track and monitor.
Track and monitor industry issues.
1st Quarter, 2010
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on April 19, 2010.
Original Filing: 300262540.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011 - Track and monitor.
Lobbying Issues
HR4872, Health Care and Education Reconciliation Act of 2010 - Track and monitor.
HR 3590, Patient Protection and Affordable Care Act. Track and monitor.
HR 3962, Affordable Health Care for America Act. Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2009
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Jan. 12, 2010.
Original Filing: 300229816.xml
Lobbying Issues
HR 2997/S 1406: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010 - Track and monitor.
Lobbying Issues
HR 3590, Patient Protection and Affordable Care Act. Track and monitor.
HR 3962, Affordable Health Care for America Act. Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2009
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Oct. 19, 2009.
Original Filing: 300209120.xml
Lobbying Issues
HR 2997/S 1406: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010 - Track and monitor.
Lobbying Issues
HR 3200: America's Affordable Health Choices Act of 2009 - Track and monitor.
Americas Healthy Future Act of 2009 - Track and monitor.
S 1679: Affordable Health Choices Act - Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2009
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on July 15, 2009.
Original Filing: 300177459.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010 - Track and monitor.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 1256: To protect the public health by providing the Food and Drug Administration with certain authority to regulate tobacco products - Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2009
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on April 13, 2009.
Original Filing: 300146650.xml
Lobbying Issues
HR1/S 1: American Recovery and Reinvestment Act of 2009 - Track and monitor.
HR 1105: Omnibus Appropriations Act, 2009 - Track and monitor.
H Con Res 85/S Con Res 13: Budget Resolution for FY 2010.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010 - Track & Monitor.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S.391: Healthy Americans Act - Track and monitor.
Track and monitor industry issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2008
In Q4, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Jan. 12, 2009.
Original Filing: 300121119.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation Act, 2009 - Track and monitor.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S.334: Healthy Americans Act - Track and monitor.
Track and monitor industry issues.
Monitor FDA issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on Oct. 14, 2008.
Original Filing: 300090929.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation Act, 2009 - Track and monitor.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 3610: Food and Drug Import Safety Act of 2007 - Track and monitor.
S.334: Healthy Americans Act - Track and monitor.
Track and monitor industry issues.
Monitor FDA issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on July 10, 2008.
Original Filing: 300063376.xml
Lobbying Issues
S.Con.Res 70: Budget resolution FY2009 - Track and monitor.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation Act, 2009 - Track and monitor.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 3610: Food and Drug Import Safety Act of 2007 - Track and monitor.
S.334: Healthy Americans Act - Track and monitor.
Track and monitor industry issues.
Monitor FDA issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $22,500. The report was filed on April 14, 2008.
Original Filing: 300035653.xml
Lobbying Issues
S.Con.Res 70: Budget resolution FY2009 - Track and monitor.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation Act, 2009 - Track and monitor.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 3610: Food and Drug Import Safety Act of 2007 - Track and monitor.
S.334: Healthy Americans Act - Track and monitor.
Track and monitor industry issues.
Monitor FDA issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
0th Quarter, 2007
In MM, WALKER, MARTIN & HATCH, LLC lobbied for GlaxoSmithKline , earning $45,000. The report was filed on Aug. 1, 2007.
Original Filing: 200043405.xml
Lobbying Issues
HR 3161/S. 1859: Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2008. Track and monitor.
HR 2638/ S.1644: Making approps. for the Dept. of Homeland Security for the FY ending September 30, 2008. Track and monitor.
HR 556/S. 1610: To ensure national security while promoting foreign investment and the creation and maintenance of jobs, to reform the process by which such investments are examined for any effect they may have on national security, to establish the Committee on Foreign Investment in the United States, and for other purposes. Track and monitor.
HR 2900/ S.1082: To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes. Track and monitor.
Track and monitor industry issues.
Monitor FDA issues.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate